Clinical Trial Update: Seronegative Myasthenia Gravis - Efgartigimod IV [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for seronegative generalized myasthenia gravis evaluating efgartigimod IV; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis
• Myasthenia Gravis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Efgartigimod, Generalized Myasthenia Gravis | Phase 3 | Status: RECRUITING